Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estradiol dynamics during superovulation are associated with oocyte quantity and maturation stage in cynomolgus macaques.

F&S science·2026
Same author

Effects of glucagon-like peptide-1 receptor agonists on anthropometric and adiposity measures in patients with antipsychotic-induced weight gain: A systematic review and meta-analysis.

Journal of psychopharmacology (Oxford, England)·2026
Same author

Identification of distinct clinical phenotypes and their neurobiological signatures in stress-exposed individuals: A multimodal machine learning approach.

European psychiatry : the journal of the Association of European Psychiatrists·2026
Same author

Oxidative aging facilitates biological barrier penetration of polyethylene microplastics, amplifying systemic lipotoxicity in aquatic species.

Particle and fibre toxicology·2026
Same author

Enhancing automated shoeprint comparison via synthetic data generation and deep segmentation.

Science & justice : journal of the Forensic Science Society·2026
Same author

Charge characteristics of fluorescent proteins modulate FUS LCD condensation.

Biophysical journal·2026

Related Experiment Video

Updated: Jun 13, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Intratumoral Injectable Click-Crosslinked Hyaluronic Acid Depot for Sustained Gemcitabine Delivery.

Kyung Eun Son1, Yejin Lee1, Yejin Kim1

  • 1Department of Molecular Science and Technology, Ajou University, Suwon, 443-749, Korea.

Tissue Engineering and Regenerative Medicine
|June 12, 2026
PubMed
Summary

Injectable hyaluronic acid hydrogels loaded with gemcitabine (GE) provide sustained local chemotherapy for solid tumors. This novel drug depot enhances antitumor efficacy and prolongs drug availability, minimizing systemic toxicity.

Keywords:
Click-crosslinked hyaluronic acid hydrogelGemcitabineIntratumoral drug deliveryTumor suppression

More Related Videos

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

Related Experiment Videos

Last Updated: Jun 13, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

Area of Science:

  • Biomaterials Science
  • Drug Delivery Systems
  • Cancer Therapy

Background:

  • Gemcitabine (GE) efficacy is limited by rapid diffusion and poor retention in solid tumors after local administration.
  • Injectable hydrogel depots offer a strategy to improve local drug availability, enhance antitumor effects, and reduce systemic toxicity.

Purpose of the Study:

  • To develop and evaluate an injectable, click-crosslinked hyaluronic acid hydrogel (GE+Cx-HA) for sustained intratumoral delivery of gemcitabine.
  • To assess the physicochemical properties, in vitro release, and in vivo antitumor efficacy of the GE+Cx-HA hydrogel system.

Main Methods:

  • Developed an injectable gemcitabine-loaded, click-crosslinked hyaluronic acid hydrogel (GE+Cx-HA) using a bioorthogonal click reaction for in situ gelation.
  • Characterized hydrogel properties, in vitro drug release, and in vitro anticancer activity against B16F10 melanoma cells.
  • Evaluated in vivo antitumor efficacy, angiogenesis inhibition, and systemic toxicity in a murine melanoma model after single intratumoral injection.

Main Results:

  • GE+Cx-HA hydrogel formed rapidly after injection, exhibiting suitable viscoelasticity and injectability without needle clogging.
  • The hydrogel suppressed burst release, enabling sustained in vitro gemcitabine release and prolonged anticancer activity.
  • Intratumoral injection of GE+Cx-HA significantly inhibited tumor growth and angiogenesis for 18 days with no observable systemic toxicity.

Conclusions:

  • GE+Cx-HA hydrogel serves as an effective intratumoral drug depot for sustained local chemotherapy.
  • This localized therapeutic platform demonstrates enhanced antitumor efficacy and holds potential for solid tumor treatment.